Form 4: Monopar Therapeutics CEO Exercises Stock Options
SEC Form 4 Filing
Chandler Robinson, CEO of Monopar Therapeutics, exercised stock options to acquire 84,000 shares of common stock.
Summary
- On May 28, 2024, Chandler Robinson, the CEO of Monopar Therapeutics, exercised stock options to acquire 84,000 shares of common stock at a price of $0.001 per share.
- Following the transaction, Robinson directly owns 250,130.8 shares of Monopar common stock.
- Robinson also indirectly controls 4,111,272.88 shares through Tactic Pharma LLC and 166,667 shares directly owned by Tactic Pharma LLC, but disclaims beneficial ownership except to the extent of his pecuniary interest.
- The exercised options were granted on April 4, 2016, and vested over a one-year period.
Sentiment
Score: 5
Explanation: This is a neutral event. The CEO exercising options is neither particularly positive nor negative on its own.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.
Key Dates
| Date | Description |
|---|---|
| 04/04/2016 | Date stock options were granted to Dr. Robinson. |
| 05/28/2024 | Date of the stock option exercise. |
| 05/30/2024 | Date of the signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.